Loading...
Market
Will GSK win at least three more Zantac-related court cases by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Court records and official announcements from GSK
Story
GSK Wins Chicago Court Case Over Zantac Cancer Claims on Monday
Aug 5, 2024, 09:57 PM
GlaxoSmithKline (GSK) has secured a victory in an Illinois state court as a jury in Chicago found the company not liable for a woman's colorectal cancer on Monday. The case centered around claims that the now-discontinued heartburn drug Zantac caused the illness. This verdict aligns with the scientific consensus that there is no consistent or reliable evidence linking ranitidine, the active ingredient in Zantac, to an increased risk of any cancer. This marks the second consecutive trial win for GSK amidst hundreds of similar lawsuits in Illinois.
View original story
Similar markets
Less than 90% • 25%
90% to 95% • 25%
95% to 99% • 25%
100% • 25%
Decrease by more than 10% • 25%
Decrease by 5% to 10% • 25%
Decrease by less than 5% • 25%
No significant change • 25%
GSK • 25%
Sanofi • 25%
Pfizer • 25%
Other • 25%
Less than $2 billion • 25%
$2 billion to $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
$3 billion to $3.5 billion • 25%
More than $3.5 billion • 25%
Stock price increases • 25%
Stock price decreases • 25%
Stock price remains stable • 25%
Insufficient data • 25%